HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model

Kothari, Vishal ; Joshi, Ganesh ; Nama, Srikanth ; Somasundaram, Kumaravel ; Mulherkar, Rita (2010) HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model International Journal of Cancer, 126 (3). pp. 733-742. ISSN 0020-7136

Full text not available from this repository.

Official URL: http://onlinelibrary.wiley.com/doi/10.1002/ijc.247...

Related URL: http://dx.doi.org/10.1002/ijc.24700

Abstract

Safety, efficacy and enhanced transgene expression are the primary concerns while using any vector for gene therapy. One of the widely used vectors in clinical trials is adenovirus which provides a safe way to deliver the therapeutic gene. However, adenovirus has poor transduction efficiency in vivo since most tumor cells express low coxsackie and adenovirus receptors. Similarly transgene expression remains low, possibly because of the chromatization of adenoviral genome upon infection in eukaryotic cells, an effect mediated by histone deacetylases (HDACs). Using a recombinant adenovirus (Ad-HSVtk) carrying the herpes simplex thymidine kinase (HSVtk) and GFP genes we demonstrate that HDAC inhibitor valproic acid can bring about an increase in CAR expression on host cells and thereby enhanced Ad-HSVtk infectivity. It also resulted in an increase in transgene (HSVtk and GFP) expression. This, in turn, resulted in increased cell kill of HNSCC cells, following ganciclovir treatment in vitro as well as in vivo in a xenograft nude mouse model.

Item Type:Article
Source:Copyright of this article belongs to John Wiley and Sons.
Keywords:Cancer Gene Therapy; Adenoviral Vector; Prodrug Activation; HDAC Inhibitors; Valproic Acid
ID Code:49694
Deposited On:20 Jul 2011 13:59
Last Modified:20 Jul 2011 13:59

Repository Staff Only: item control page